Compare

Guided Therapeutics Inc vs iTonic Holdings Ltd vs Neuraxis, Inc vs Nuwellis, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearGuided Therapeutics Inc
GTHP
iTonic Holdings Ltd
ITOC
Neuraxis, Inc
NRXS
Nuwellis, Inc.
NUWE
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$767.0K$523.0K$3.57M$8.27M
Revenue growth (YoY)n/m+16.7%+32.9%-5.4%
Gross margin74.4%62.6%84.2%62.0%
Operating margin-309.3%-991.7%-219.4%-134.3%
Net margin-416.7%-974.7%-218.5%-211.9%
Net income-$3.20M-$5.10M-$7.80M-$17.52M
EPS (Diluted)-$0.04-$0.32-$0.95-$25.39
Operating cash flow-$1.07M-$3.23M-$6.43M-$10.81M
Free cash flow-$1.07M-$3.24M-$6.46M-$10.90M
Cash & equivalentsn/a$1.49M$4.97M$1.08M
Total assets$1.32M$9.10M$6.40M$6.12M
Total liabilities$7.33M$969.8K$3.00M$3.49M
Shareholders' equity-$6.01M$6.12M$3.40M$2.62M
Return on year-end equityn/a-83.3%-229.5%-667.7%
Shares outstanding86.15Mn/a10.65M1.69M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearGuided Therapeutics InciTonic Holdings LtdNeuraxis, IncNuwellis, Inc.
Latest$767.0K
Ended 2025-12-31
$523.0K
Ended 2025-12-31
$3.57M
Ended 2025-12-31
$8.27M
Ended 2025-12-31
1 year earlier$7.0K
Ended 2024-12-31
$448.2K
Ended 2024-12-31
$2.69M
Ended 2024-12-31
$8.74M
Ended 2024-12-31
2 years earlier$98.0K
Ended 2023-12-31
$628.6K
Ended 2023-12-31
$2.46M
Ended 2023-12-31
$8.86M
Ended 2023-12-31
3 years earlier$13.0K
Ended 2022-12-31
$679.8K
Ended 2022-12-31
$2.68M
Ended 2022-12-31
$8.54M
Ended 2022-12-31
4 years earlier$81.0K
Ended 2021-12-31
n/an/a$7.92M
Ended 2021-12-31